UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Annals of oncology, 2011-05, Vol.22 (5), p.1054-1061

2011

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Annals of oncology, 2009-07, Vol.20 (7), p.1264-1269

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)

Annals of oncology, 2008-07, Vol.19 (7), p.1304-1307

2008

Link zum Volltext

Verfügbarkeit prüfen

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

The lancet oncology, 2015-01, Vol.16 (1), p.76-86

2015

Link zum Volltext

Verfügbarkeit prüfen

CAG repeat polymorphism in the DNA polymerase γ gene in a Polish population: an association with testicular cancer risk

Annals of oncology, 2005-07, Vol.16 (7), p.1211-1212

2005

Link zum Volltext

Verfügbarkeit prüfen

4502 ORAL Phase 2 study of irinotecan and cisplatin in epidermoid carcinoma of the penis (EORTC 30992)

European journal of cancer supplements, 2007, Vol.5 (4), p.299-299

2007

Link zum Volltext

Verfügbarkeit prüfen

Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy

Annals of oncology, 2014-09, Vol.25, p.iv269

2014

Link zum Volltext

Verfügbarkeit prüfen

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study

European journal of heart failure, 2011-03, Vol.13 (3), p.327-336

2011

Link zum Volltext

Verfügbarkeit prüfen

P110 The assessment of therapeutic practice of urologists and clinical oncologists and the pattern of referrals in the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC) in Poland (ProSTandard Registry)

European urology supplements : official journal of the European Association of Urology, 2013-11, Vol.12 (6), p.173-174

2013

Link zum Volltext

Verfügbarkeit prüfen

557 Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

European urology supplements : official journal of the European Association of Urology, 2015-04, Vol.14 (2), p.e557-e557a

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4509-4509

2011

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4512-4512

2010

Link zum Volltext

Verfügbarkeit prüfen

Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4572-4572

2005

Link zum Volltext

Verfügbarkeit prüfen

A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis

Seminars in oncology, 1994-10, Vol.21 (5 Suppl 9), p.3

1994

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant Drostate cancer

Annals of oncology, 2009, Vol.20 (7), p.1264-1269

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II/III trial assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) “unfit” for cisplatin based chemotherapy (CHT): Updated phase II results and risk group analysis of EORTC study 30986

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5031-5031

2008

Link zum Volltext

Verfügbarkeit prüfen

922PSafety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis of local relapse after radical radiotherapy (RRTH) of prostate cancer by biochemical PSA kinetics and transrectal ultrasonography (TRUS) verified by prostate biopsy

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.14631-14631

2006

Link zum Volltext

Verfügbarkeit prüfen

Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors

Oncogene, 2000-08, Vol.19 (35), p.4075-4078

2000

Link zum Volltext

Verfügbarkeit prüfen

781PANALYSIS OF EUROPEAN PATIENTS ENROLLED IN A GLOBAL EARLY ACCESS PROTOCOL WITH ABIRATERONE ACETATE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER CHEMOTHERAPY

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv269-iv269

2014

Link zum Volltext

Verfügbarkeit prüfen

900 Adjuvant chemotherapy(CHTH) in patients with high-risk urothelial cancer of urinary tract

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S270-S271

2003

Link zum Volltext

Verfügbarkeit prüfen

A Comparative Study of the Use of Navoban (ICS 205-930), a 5-HT3 Antagonist, versus a Standard Antiemetic Regimen of Dexamethasone and Metoclopramide in the Treatment of Cisplatin-Containing Chemotherapy

Drug Investigation, 1993-09, Vol.6 (3), p.162-169

1993

Link zum Volltext

Verfügbarkeit prüfen

Antiemetic effect of ondansetron in patients treated with combined antineoplastic regimens which include cisplatin

Polski tygodnik lekarski (Warsaw, Poland : 1960), 1993-06, Vol.48 (25-26), p.560

1993

Link zum Volltext

Verfügbarkeit prüfen

Mitochondria–nucleus network for genome stability

Free radical biology & medicine, 2015-05, Vol.82, p.73-104

2015

Link zum Volltext

Verfügbarkeit prüfen

Genetic instability in budding and fission yeast—sources and mechanisms

FEMS microbiology reviews, 2015-11, Vol.39 (6), p.917-967

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(100)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(56)
Humans
(29)
Male
(23)
Oncology
(21)
Middle Aged
(17)
Saccharomyces Cerevisiae
(15)
Saccharomyces Cerevisiae - Genetics
(15)
Adult
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Cell Biology
(13)
Yeast
(13)
Aged
(12)
Biological And Medical Sciences
(12)
Treatment Outcome
(12)
Medical Sciences
(10)
Mutation
(10)
Aged, 80 And Over
(9)
Biochemistry & Molecular Biology
(9)
Genomic Instability
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

CAG repeat polymorphism in the DNA polymerase γ gene in a Polish population: an association with testicular cancer risk

4502 ORAL Phase 2 study of irinotecan and cisplatin in epidermoid carcinoma of the penis (EORTC 30992)

Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study

P110 The assessment of therapeutic practice of urologists and clinical oncologists and the pattern of referrals in the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC) in Poland (ProSTandard Registry)

557 Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983)

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)

Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma

A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant Drostate cancer

Randomized phase II/III trial assessing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) “unfit” for cisplatin based chemotherapy (CHT): Updated phase II results and risk group analysis of EORTC study 30986

922PSafety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

Diagnosis of local relapse after radical radiotherapy (RRTH) of prostate cancer by biochemical PSA kinetics and transrectal ultrasonography (TRUS) verified by prostate biopsy

Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors

781PANALYSIS OF EUROPEAN PATIENTS ENROLLED IN A GLOBAL EARLY ACCESS PROTOCOL WITH ABIRATERONE ACETATE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER CHEMOTHERAPY

900 Adjuvant chemotherapy(CHTH) in patients with high-risk urothelial cancer of urinary tract

A Comparative Study of the Use of Navoban (ICS 205-930), a 5-HT3 Antagonist, versus a Standard Antiemetic Regimen of Dexamethasone and Metoclopramide in the Treatment of Cisplatin-Containing Chemotherapy

Antiemetic effect of ondansetron in patients treated with combined antineoplastic regimens which include cisplatin

Mitochondria–nucleus network for genome stability

Genetic instability in budding and fission yeast—sources and mechanisms

Suchergebnisse filtern